Tacrolimus and Mycophenolate Mofetil as Maintenance Immunosuppressants by Chilcott, J. et al.
  
 
 
 
 
 
WORKING GROUP ON ACUTE PURCHASING 
 
Tacrolimus and Mycophenolate Mofetil as 
Maintenance Immunosuppressants following 
 Renal Transplantation 
 
 
August 1999 
 
 
GUIDANCE NOTE FOR PURCHASERS 99/07 
Series Editor: Nick Payne 
InterDEC Report No. 16/1999 
 Trent Development and Evaluation Committee 
 
 
The purpose of the Trent Development and Evaluation Committee is to help health 
authorities and other purchasers within the Trent Region by commenting on expert reports 
which evaluate changes in health service provision. The Committee is comprised of members 
appointed on the basis of their individual knowledge and expertise.  It is chaired by Professor 
Sir David Hull. 
 
 
The Committee recommends, on the basis of evidence provided, priorities for: 
 
 the direct development of innovative services on a pilot basis; 
 service developments to be secured by health authorities. 
 
 
The statement that follows was produced by the Development and Evaluation Committee at 
its meetings on 28 October 1998 and 13 April 1999 at which this Guidance Note for 
Purchasers (in a draft form) was considered. 
 
 
 
TACROLIMUS AND MYCOPHENOLATE MOFETIL AS MAINTENANCE 
IMMUNOSUPPRESSANTS FOLLOWING RENAL TRANSPLANTATION 
 
 
AUTHORS: Chilcott J, Corcoran M, Rigg KM, Burden RP. Trent Institute for Health 
Services Research, Universities of Leicester, Nottingham and Sheffield 1999.  Guidance Note 
for Purchasers: 99/07. 
 
EXPERT ADVISORS TO TRENT DEC: 
Dr R P Burden, Consultant Nephrologist, Nottingham City Hospital; Mr J Chilcott, Senior 
Operational Research Analyst, the School of Health and Related Research (ScHARR) The 
University of Sheffield; Dr M Corcoran, Consultant in Public Health Medicine, Nottingham 
Health Authority; Mr K M Rigg, Consultant Transplant Surgeon, Nottingham City Hospital. 
 
(The recommendations made by the Committee may not necessarily match the personal opinions expressed by the experts) 
 
 
DECISION: In the light of limited benefits and high costs, the Committee considered that if 
tacrolimus and MMF were used as maintenance immunosuppressants following renal 
transplantation, they should be used for high risk patients only.  This sub-group of patients 
accounts for about 30% of the total number of renal transplant patients. 
  
August 1999 
 
 
TACROLIMUS AND MYCOPHENOLATE MOFETIL  
AS MAINTENANCE IMMUNOSUPPRESSANTS 
FOLLOWING RENAL TRANSPLANTATION 
 
 
 
J Chilcott 
M Corcoran 
K M Rigg 
R P Burden 
 
 
 
Series Editor: Nick Payne 
 
 
 
Trent Institute for Health Services Research 
Universities of Leicester, Nottingham and Sheffield 
 
 
 
GUIDANCE NOTE FOR PURCHASERS 99/07 
InterDEC No: 16/1999 
  
 
Published by the Trent Institute for Health Services Research. 
 
 
© 1999 Trent Institute for Health Services Research, Universities of Leicester, Nottingham 
and Sheffield. 
 
ISBN: 1 900 733 250 
 
Referencing information: 
 
Chilcott J, Corcoran M, Rigg KM, Burden RP. Tacrolimus and Mycophenolate Mofetil as 
Maintenance Immunosuppressants following Renal Transplantation. Sheffield: Trent 
Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield, 
1999. Guidance Note for Purchasers : 99/07. 
 
 
Further copies of this document are available (price £15.00) from:- 
 
Alison Ring 
Information Resources 
Trent Institute for Health Services Research 
Regent Court 
30 Regent Street 
SHEFFIELD S1 4DA 
 
Tel 0114 222 0703 
Fax 0114 272 4095 
E-mail scharrlib@sheffield.ac.uk 
 
Please make cheques payable to “The University of Sheffield” 
 
 
Conflict of Interest None of the authors of this document has any financial 
interests in the drugs or products being evaluated here. 
ScHARR is in receipt of funding for unrelated work in the field 
of transplantation from Novartis AG.   In view of this, however, 
the report has been reviewed by the Wessex Institute for 
Health Research and Development. 
  
AUTHORS 
 
Mr J Chilcott is a Senior Operational Research Analyst at The School of Health and Related 
Research (ScHARR) The University of Sheffield;  
Dr M Corcoran is a Consultant in Public Health Medicine at Nottingham Health Authority;  
Mr K M Rigg is a Consultant Transplant Surgeon at Nottingham City Hospital;  
Dr R P Burden is a Consultant Nephrologist at Nottingham City Hospital. 
 
 
ACKNOWLEDGEMENTS 
 
The authors would like to thank the Wessex Institute for Health Research and Development 
for reviewing this report. 
 
We also wish to thank Suzy Paisley for the literature search and Gill Rooney, Pat Holmes 
and Mike Jacobs for their invaluable help in the editing and formatting of this document. 
 
  
ABOUT THE TRENT INSTITUTE FOR HEALTH SERVICES RESEARCH 
 
The Trent Institute for Health Services Research is a collaborative venture between the 
Universities of Leicester, Nottingham and Sheffield with support from NHS Executive Trent.  
 
The Trent Institute: 
 
 undertakes Health Services Research (HSR), adding value to the research through the 
networks created by the Institute; 
 
 provides advice and support to NHS staff on undertaking Health Services Research 
(HSR); 
 
 provides training in HSR for career researchers and for health service professionals; 
 
 provides educational support to NHS staff in the application of the results of research; 
 
 disseminates the results of research to influence the provision of health care. 
 
The Directors of the Institute are: Professor R L Akehurst (Sheffield); 
 Professor C E D Chilvers (Nottingham); and  
 Professor M Clarke (Leicester).  
Professor Clarke currently undertakes the role of Institute Co-ordinator. 
 
A Core Unit, which provides central administrative and co-ordinating services, is located in 
Regent Court within The University of Sheffield in conjunction with The School of Health and 
Related Research (ScHARR). 
  
FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Purchasing 
Authorities Chief Executives (PACE) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst, 
Chairman, Trent Working Group on Acute Purchasing. 
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EXECUTIVE SUMMARY  
 
Transplantation with either a cadaveric or living donor kidney is the preferred treatment of 
end stage renal failure. There is, however, a steadily increasing waiting list of people eligible 
for transplantation due to the lack of suitable donor organs. This is exacerbated by the fact 
that about 10% of transplants will fail within one year, despite matching, as closely as 
possible, the donor and recipient for tissue compatibility. 
 
Until recently, post-operative management to reduce the risk of rejection has been based on 
cyclosporin, azathioprine and corticosteroids. Two new drugs are now available: tacrolimus 
and mycophenolate mofetil. 
 
The primary focus of this paper is on the use of these drugs in maintenance therapy for 
adults. There is also evidence of their efficacy in rescue therapy in response to episodes of 
acute rejection. The Wessex Institute Development and Evaluation Committee Report No.74 
“Tacrolimus after kidney transplantation” recommends tacrolimus as a rescue therapy 
agent.  
 
The clinical effectiveness of these drugs in primary maintenance therapy, in the short to 
medium-term, has been determined in five randomised controlled trials.  Trials of tacrolimus, 
which replaces cyclosporin, showed a significant reduction of 15% to 20% in the number of 
episodes of acute rejection, and of between 10% and 15% in steroid resistant rejection after 
12 months of treatment. 
 
Trials of mycophenolate mofetil, which is used in addition to cyclosporin, showed a 
significant reduction of between 20% and 25% in episodes of acute rejection and reduction 
in steroid resistant rejection, similar to tacrolimus at six months. A pooled analysis of these 
trials confirmed this reduction at 12 months. 
 
A new preparation of cyclosporin has been made available since the published trials of 
tacrolimus and mycophenolate mofetil were commissioned. Studies investigating the 
efficacy, in terms of acute rejection avoided, of the new formulation (Neoral) in comparison 
to the older formulation (Sandimmun) claim reductions ranging from 8% to 16%. Synthetic 
comparisons constructed between the new cyclosporin formulation and both tacrolimus or 
mycophenolate mofetil indicate that the marginal benefit of both newer drugs may potentially 
be reduced compared with the older formulation. 
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Follow-up results at three years of two of the mycophenolate mofetil trials showed a 
marginal, but not statistically significant, difference in the rate of graft failure or death, 
although the trials were not designed or powered to detect such differences initially.  All five 
trials had a relatively large proportion of withdrawals, ranging from 16.5% for tacrolimus up 
to 35% in one trial for the 3mg dose of mycophenolate.  These were mainly due to adverse 
side effects which were dose dependent. Lower maintenance doses for tacrolimus have 
been recommended as a result of these trials.  
 
Both tacrolimus and mycophenolate are more expensive than conventional therapy, but their 
additional cost needs to be balanced against the reduced costs of treating episodes of acute 
rejection and the potential averted costs of transplant failure, dialysis and retransplantation.  
Some of the costs saved, such as the drugs used for steroid resistant rejection, are 
realisable, but others, such as the number of bed days saved, may not be.  There are also 
advantages to the patient which have not been quantified.  Hospital based cost savings 
arising from tacrolimus treatment mean that this therapy is estimated to be approximately 
cost neutral compared to conventional (Sandimmun) therapy. Against Neoral cyclosporin, 
however, tacrolimus is estimated to cost an extra £1,000 per patient per year.  
Mycophenolate mofetil is estimated to cost approximately £2,000 more per patient than 
cyclosporin (Sandimmun) for the same period, similarly, against Neoral cyclosporin, the 
estimate is £3,000 per patient per year.   
 
There is insufficient direct evidence as yet to make firm conclusions about the value of these 
drugs as maintenance therapy in the longer-term, although initial evidence indicates that a 
modest increase in patient and graft survival may be achieved. The comparative cost with 
conventional therapy depends on the actual steady state dosages achieved.  
 
Children justify special consideration because one of the major benefits of transplantation in 
children is to enable them to grow satisfactorily and for them to achieve their school and 
developmental potential.  It is essential that the best graft function possible is achieved and 
the use of these newer agents would enable a reduction of acute rejection.  This may, in 
turn, reduce the incidence of chronic rejection and the need for the child to undergo further 
transplants either in late childhood or early adulthood.  A lot of focus in the document is on 
saving kidneys in the long-term from rejection and this is of major importance in children. 
 
Given the lack of information on risks of infectious complications and malignancy associated 
with the long-term use of the two new agents, it may be appropriate initially to implement the 
new agents as primary maintenance in immunologically high risk patients, whilst using 
conventional primary maintenance therapy for immunologically low risk patients.
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1. INTRODUCTION 
 
1.1 Incidence and Pathology 
 
Transplantation is the preferred therapy for end stage renal failure as it improves a patient’s 
quality of life, encourages occupational rehabilitation and is more cost-effective compared 
with the alternative of dialysis. However, a shortage of organs restricts the number of 
patients who can receive transplantations. 
 
More than 11,000 people are receiving renal dialysis in the UK, costing some £220 million  
each year and these figures are expected to double in the next five to ten years. Based on 
estimates of incidence, the acceptance rate for transplantation or dialysis needs to be 80-
100 per million population per annum for patients aged under 80 years, from a white 
population, and excluding patients with a malignancy or major stroke. This acceptance rate, 
however, needs to be higher in the Afro-Caribbean and Asian groups where incidence is as 
high as 240-300 per million population per annum. The commonest causes of renal failure 
are glomerulonephritis, diabetes and hypertension.
1
 
 
1.2 Prognosis and Mortality 
 
One year graft survival has steadily improved over the last two decades and is now around 
90% for low risk patients. However, for transplant patients who survive beyond the first year, 
there has been no corresponding improvement in the rate of graft failure. The improvement 
in graft failure rates over the last two decades is illustrated in Figure 1.  
 
In the long-term, approximately 50% of grafts are still functioning at the death of transplant 
patients, the most common cause of death in these patients being cardiovascular 
complications. Chronic rejection, which is a slow progressive process, is responsible for 
25% to 35% of graft losses after one year. The major risk factor for the development of 
chronic rejection is acute rejection. Acute rejection occurs in 30-50% of all transplants, 
usually in the first three months, and can be treated successfully in over 90% of cases. The 
development of chronic rejection is usually associated with episodes of acute rejection that 
are severe, recurrent or late. Therefore, there is evidence to suggest that therapeutic 
manoeuvres to reduce the incidence or severity of acute rejection episodes could lead to a 
lower incidence of chronic rejection with an associated improvement in long-term graft 
survival.  
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Two new immunosuppressant agents, tacrolimus (Prograf) and mycophenolate mofetil 
(MMF)(Cellcept) have been claimed to be effective in reducing the incidence and severity of 
acute rejection when administered as a daily maintenance regimen, and in treating acute 
rejection when administered as ‘rescue’ therapy. There is currently no fully published 
randomised controlled trial (RCT) evidence which addresses the effect of either drug on 
long-term graft survival. 
 
Figure 1 Observed Graft Survival Curves in First Cadaveric Grafts Performed 
Between 1971 and 1986 (After Landais
2
). 
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1.3 Prevention of Acute Rejection 
 
Cyclosporin, azathioprine (AZA) and prednisolone are used for maintenance therapy in a 
number of different regimens; even so, acute rejection will still occur in 30-50% of patients 
and particularly in those who are at high risk immunologically. The newer agents, tacrolimus 
and mycophenolate mofetil, have been shown, in multicentre studies, to reduce the 
incidence of acute rejection in the first year post transplant. Tacrolimus is used in place of 
cyclosporin and mycophenolate mofetil in place of azathioprine. This paper evaluates their 
use in comparison with conventional immunosuppression. The management strategies 
evaluated are: 
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 Tacrolimus  Maintenance immunosuppression with tacrolimus,  
 azathioprine and prednisolone; 
 Mycophenolate mofetil  Maintenance immunosuppression with  
 cyclosporin, mycophenolate mofetil and prednisolone; 
 Conventional  Maintenance immunosuppression with cyclosporin,  
 azathioprine and prednisolone. 
 
 
1.4 Treatment of Acute Rejection 
 
The first line treatment for acute rejection is high dose methylprednisolone, but up to 20% of 
rejection episodes may be steroid resistant. Conventionally, polyclonal antibodies (anti-
thymocyte globulin or anti-lymphocyte globulin) or monoclonal antibodies have been given 
for steroid resistant or refractory rejection. However, tacrolimus is being used increasingly, 
as clinical experience and case studies suggest that it is better tolerated by the patient and 
more effective.
3,4,5
 
 
A review of the evidence for tacrolimus in transplant rescue is contained in the Wessex 
Institute Development and Evaluation Committee (DEC) Report No.74 “Tacrolimus after 
kidney transplantation”.
6
 This report identifies that the evidence for tacrolimus in rescue 
therapy comes from non-controlled case series and, as such, the evidence is of poorer 
quality than the RCT evidence available for primary immunosuppression. It should be noted, 
however, that ethical and practical difficulties preclude randomisation and control for novel 
rescue therapies. The Wessex report notes that the studies reviewed have quite large 
sample sizes and adequate follow-up and show a good response to tacrolimus treatment. 
The Wessex DEC report, therefore, recommends tacrolimus as rescue therapy.  
 
The evidence for mycophenolate mofetil in transplant rescue consists of randomised and 
non-randomised studies and case series. A search for studies has been undertaken, though 
it should be noted that these have not been subjected to a full systematic review, this being 
outside the scope of this report. 
 
A six month open label, randomised, multicentre trial
7
 compared the efficacy and safety of 
mycophenolate mofetil with high dose intravenous steroids for the treatment of refractory 
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acute rejection. A total of 150 patients were randomised in a 1-to-1 ratio. Graft loss and 
death at six months, the primary efficacy variable, was reduced from 26% in the steroid 
group to 14% in the mycophenolate mofetil treatment group. The 45% reduction at six 
months was not statistically significant; however, at 12 months the reduction was significant 
(p=0.042). Furthermore, the number of patients who received a full course of anti-
lymphocyte therapy was more than double in the steroid group (18 patients) than in the 
mycophenolate mofetil group (eight patients). Adverse events were recorded in 74.6% of the 
steroid group and 93.5% of the mycophenolate mofetil group.  
 
In a further study, Sollinger
8
 investigated the use of mycophenolate mofetil in a series of 75 
patients who had previously undergone anti-rejection therapy with high dose steroids, OKT3 
or both treatments. Successful rescue was achieved in 52 of 75 (69%) of patients, with an 
overall infection rate of 40%; no significant nephrotoxicity, hepatotoxicity or 
myelosuppression was found. 
 
These studies indicate that mycophenolate mofetil may be effective in the treatment of 
refractory rejection. 
 
1.5 Scale of Problem in a 'Typical' District 
 
In the UK and Republic of Ireland there are currently 6,000 patients awaiting transplantation 
but only 1,800 transplants are performed each year. In the Trent Region there are over 450 
patients on the waiting list, but only 130 transplants are carried out each year. Therefore, 
strategies to improve both organ supply and graft survival are imperative if this deficit is to 
be addressed. 
 
There are three renal units which undertake transplantation within the Trent Region; the 
Northern General Hospital in Sheffield, Nottingham City Hospital and Leicester General 
Hospital, each centre serving a population of approximately 1.5 - 2 million people. For a 
population of two million people there would be approximately 180 patients waiting for a 
transplant and approximately 52 transplants undertaken annually. For a 'typical' district 
population of 500,000 the corresponding figures are 45 patients on the waiting list and 13 
renal transplants carried out each year. 
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2. THE USE OF TACROLIMUS AND MYCOPHENOLATE MOFETIL AS 
MAINTENANCE IMMUNOSUPPRESSANTS: SUMMARY OF EVIDENCE OF 
EFFECTIVENESS 
 
2.1 Summary of Literature Search for Evidence 
 
Searches of EMBASE, the Cochrane Clinical Trials Library, and MEDLINE were undertaken. 
The searches identified papers in the intersection of three domains: kidney transplantation; 
randomised controlled trials (as defined by the Cochrane comprehensive strategy) and the 
drug of interest. The tacrolimus search included Prograf, FK506 and the CAS registry 
number, the mycophenolate mofetil search included in the terms Cellcept, and the CAS 
registry number. These searches covered the period 1985 to 1998, though a subsequently 
published meta-analysis of tacrolimus has been identified and the implications of the results 
reviewed. The searches were assessed by title and abstract, where available, by one clinical 
and one analytical support member of the project team. The following inclusion criteria were 
used in selecting papers; reports of randomised controlled trials of either tacrolimus or 
mycophenolate mofetil used as primary maintenance agents following kidney 
transplantation; comparisons of either drug against placebo or against each other (non-
randomised) were identified; small pre-clinical and Phase II studies were excluded.  
 
Ideally, clinical outcome measures would address either graft loss over a sufficiently long 
follow-up period to identify clinically significant differences or quality and duration of life 
during the transplant period. The occurrence of acute rejection is used as a proxy or 
surrogate outcome measure for these final endpoints, firstly on the basis of its relation to 
long-term chronic rejection and graft loss, and secondly in its own right as being associated 
with significant morbidity. The large majority of episodes of acute rejection occur in the first 
three months post transplant, this was, therefore, considered a minimum period for follow-
up. The potential implications of the reported short-term acute rejection results on long-term 
graft survival have been addressed through a simple modelling study reported in Section 
3.4. 
 
The search has identified two trials of tacrolimus
9,10
 and three trials involving mycophenolate 
mofetil
11,12,13
 as part of primary maintenance regimens. Details of these trials are 
summarised in Tables 1 and 2. 
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The evidence for Tacrolimus in rescue therapy is reviewed in the Wessex Institute DEC 
Report No 74 “Tacrolimus after kidney transplantation”.
6
 A topic search of the above health 
databases was undertaken to identify evidence on the use of mycophenolate mofetil in 
rescue therapy. 
 
2.2 Tacrolimus 
 
2.2.1 Evidence of Effectiveness of Tacrolimus 
 
The major multi-centre clinical trials of tacrolimus as a maintenance immunosuppressant 
had similar entry criteria, including male and female patients undergoing renal 
transplantation. The European Tacrolimus Multicentre Renal Study Group trial
9
 (European 
Tacrolimus trial) included people over 18 years of age, whilst the FK506 Kidney Transplant 
Study Group trial
10
  (US Tacrolimus trial) included those over six years of age who were 
receiving their first or second transplant.  
 
Exclusion criteria common to the trials were: serological evidence of Human 
Immunodeficiency Virus; ABO-incompatible grafts; and patients undergoing multiple organ 
transplants. Women who were pregnant, lactating or who were using inadequate 
contraception were also excluded, as were patients with significant hepatic disease. 
 
The trials both consisted of two arms: 
 conventional treatment, consisting of cyclosporin maintenance therapy in the European 
study and cyclosporin with azathioprine in the US study; 
 daily tacrolimus as a replacement for cyclosporin therapy. 
 
The drug dosages recorded in the trials are consistent. The cyclosporin dosages were 
reduced during the course of both trials; the European Tacrolimus trial recorded initial 
dosages of 6.9 mg/kg reducing to an average of 3.5 mg/kg over months 10-12,  this being 
consistent with the overall mean dosage recorded within the US Tacrolimus trial of 5.5 
mg/kg.  Similarly, the tacrolimus dosages compare well, with a reduction from 0.26 mg/kg to 
0.12 mg/kg over the European Tacrolimus trial period, compared with an overall mean 
dosage of 0.18 mg/kg in the US Tacrolimus  trial. 
   
The more recent European Tacrolimus trial focused on first biopsy proven acute rejection as 
the primary outcome measure, whereas the earlier US Tacrolimus trial had patient survival 
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and graft survival as the primary outcome measures, with first biopsy proven acute rejection 
as a secondary outcome measure. However, the results are remarkably consistent and are 
detailed in Tables 1 and 3. No statistical test for homogeneity has been undertaken, the low 
power of available tests, the small number of trials and the visually assessed consistency in 
the results make such a statistical test obsolete. A meta-analysis of the randomised 
controlled trial evidence for tacrolimus versus cyclosporin confirms this high level 
consistency.
14
 The one year patient and graft survival rates show no significant difference 
between cyclosporin and tacrolimus treatment. There was, however, a significant reduction 
in the acute rejection rates for tacrolimus treatment over cyclosporin treatment.  
 
Table 3 summarises the acute rejection rates observed in the reviewed trials, the biopsy 
proven acute rejection rate for cyclosporin was between 43.4% and 46.4%, whilst the same 
figure for tacrolimus was between 24.1% and 30.7%. 
 
The absolute decrease in first biopsy proven acute rejection rate, obtained through the use 
of tacrolimus over the 12 months following transplantation, was approximately 15-20%.  This 
implies that the number needed to treat (NNT) to avoid acute rejection in one patient is 
between five and seven.  
 
The severity of episodes of acute rejection was also reported as another secondary 
outcome measure in both trials. Tacrolimus was found to decrease significantly the 
incidence of corticosteroid resistant acute rejection in both trials. The European Tacrolimus 
trial reported a statistically significant decrease from 20.7% of the cyclosporin treated 
patients experiencing corticosteroid resistant acute rejection compared with 10.2% of the 
tacrolimus treated patients.  The equivalent figures in the US Tacrolimus  trial were 25.1% 
and 10.7%. This implies an NNT of between seven and ten to avoid corticosteroid resistant 
rejection in one patient.  
 
2.2.2 Adverse Events and Contraindications Associated with Tacrolimus 
 
Adverse events were common throughout all treatment arms of all trials. Tacrolimus was 
associated with the following adverse events profile compared to conventional therapy in 
both trials: 
 increased incidence of tremor; 
 increased diabetes mellitus; 
 increased incidence of alopecia and decreased incidence of hirsutism; 
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 decreased incidence of gingival hyperplasia. 
 
Other adverse events associated with tacrolimus, but, either not recorded in both trials, or 
found not to be significantly different from cyclosporin treatment in both trials were: 
 
 elevated serum creatinine found in the European Tacrolimus trial but not found in the US 
Tacrolimus trial; 
 a higher incidence of deep vein thrombosis identified in the US Tacrolimus trial, but not 
in the European Tacrolimus trial; 
 a higher incidence of diarrhoea identified in the European Tacrolimus trial, but not found 
in the US Tacrolimus trial. 
 
There is evidence that a higher withdrawal rate occurred with tacrolimus treatment than with 
cyclosporin treatment. The withdrawal rate in the European Tacrolimus study was 16.5% in 
the tacrolimus arm and 2.8% in the cyclosporin arm, a statistically significant difference. The 
main reasons for withdrawal in the tacrolimus treated patients were renal disorders, 
neurological and cardiovascular complications and opportunistic infections. 
 
2.2.3 Dose Response of Tacrolimus 
 
A systematic search of the usual databases was undertaken for published evidence on the 
effectiveness of tacrolimus when given in doses lower than those studied in the Phase III 
trials. In addition, a request for grey literature was made to the Medicines Control Agency. 
The systematic search uncovered no published evidence on efficacy of maintenance with 
doses lower than those used in the Phase III trials. Therefore, the search was expanded to 
cover evidence on the dose response relationship from early studies; two papers
15,16
 based 
upon the same Phase II study were identified. The results in this study relate to the first 42 
days after transplantation, therefore, whilst they address the effect of lowering the initial 
dose, efficacy of long-term low dose maintenance is not addressed. 
 
The occurrence of episodes of acute rejection and of adverse events necessitating a 
reduction in dose at the three tacrolimus dosage levels in the Phase II study are given in 
Figures 2 and 3. The low dose Phase II results were corroborated by the European and US 
Phase III trials, which were undertaken at a similar dose and gave similar results both in 
terms of acute rejections and study withdrawal. The evidence on dose response supplied by 
this Phase II study indicates that the effectiveness is likely to be reduced if lower initial 
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doses are used, however there is insufficient evidence to quantify this reduction and, 
furthermore, this does not necessarily imply that lowering long-term maintenance doses will 
lead to significant increases in acute rejection. 
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Table 1 Randomised Controlled Trials Involving Tacrolimus 
 
TRIAL EUROPEAN TACROLIMUS TRIAL 
9
 US TACROLIMUS TRIAL
10
 
DESIGN Randomised, open-label placebo controlled Randomised, open-label, placebo controlled 
PATIENT NUMBERS 448 (303 tacrolimus, 145 cyclosporin) 412 (205 tacrolimus, 207 cyclosporin) 
INCLUSION CRITERIA age 18undergoing renal transplantation 
 
age 6undergoing first or second renal 
transplantation 
EXCLUSION CRITERIA HIV+ive, ABO-incompatible grafts, multiple organ transplants, 
pregnant women, women using inadequate contraception, 
significant hepatic disease 
ABO-incompatible grafts, multiple organ transplants, 
pregnant or nursing women, HIV+ive 
STUDY PERIOD 12 months 12 months 
MEAN DAILY DOSE 
Initial 
Month 10-12 mean 
Tacrolimus 
0.26 mg/kg 
0.12 mg/kg 
Cyclosporin 
6.90 mg/kg 
3.50 mg/kg 
Tacrolimus 
0.18 mg/kg* 
 
Cyclosporin  
5.5 mg/kg* 
 
   *12 month mean 
EFFICACY 
Patient survival 
Graft survival 
Acute rejection 
Steroid resistant 
Tacrolimus  
282/302 (93.0%) 
245/303 (82.5%) 
73/303  (24.1%)  
31/303 (10.2%) 
Cyclosporin 
140/145 (96.5%)   [p=0.140] 
125/145 (86.2%)   [p=0.380] 
63/145  (43.4%)   [p<0.001] 
30/145  (20.7%)   [p=0.004] 
Tacrolimus 
196/205 (95.6%) 
187/205 (91.2%) 
63/205  (30.7%) 
22/205  (10.7%) 
Cyclosporin 
200/207(96.6%)  [p=0.576] 
182/207(87.9%)  [p=0.289] 
96/207  (46.4%)  [p=0.001] 
52/207  (25.1%)  [p<0.001] 
WITHDRAWAL DUE TO 
ADVERSE EVENTS 
50/303 (16.5%) 4/145 (2.8%)        [p<0.001] [?] 
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The manufacturers recommend an initial dose of 0.15-0.30mg/kg/day which is in line with 
clinical trials. Most UK units tend to commence patients at the lower level and titrate that 
according to clinical response and blood levels. The manufacturers also state that the dose 
can frequently be reduced during maintenance therapy, although a target dose is not 
specified. Current clinical practice has shown that it is safe to reduce the dose to 0.08-
0.1mg/kg/day in the maintenance phase, with careful monitoring of the clinical response. 
 
Figure 2 Dose Response of Acute Rejection  
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Figure 3 Dose Response of Toxicity 
 (i.e. Adverse Events Necessitating a Reduction in Dose)  
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2.3 Mycophenolate Mofetil     
 
2.3.1 Evidence of Effectiveness of Mycophenolate Mofetil  
 
Three phase III, randomised, double-blind, multi-centre clinical trials have been undertaken 
by three groups, each supported by F. Hoffmann-La Roche: 
 European Mycophenolate Mofetil Cooperative Study Group;
11
 
 US Renal Transplant Mycophenolate Mofetil Study Group;
12
 
 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
13
  
 
The primary efficacy endpoint in each of the individual trials was biopsy proven rejection or 
treatment failure at six months. The results of the three trials have all been published 
separately. Furthermore, a pooled analysis of the results of all three trials after 12 months 
has been reported.
17
 This pooling is justified since the analysis was intended from the 
outset, thus, the trial designs, including endpoints and inclusion/exclusion criteria, were 
similar for all trials. 
 
The trials had similar entry criteria to the tacrolimus studies, including male and female 
patients over 18 years of age undergoing renal transplantation. The European and 
Tricontinental studies included patients receiving their first or second transplant, whilst the 
US study was restricted to first transplants. 
  
Exclusion criteria were also similar to the tacrolimus studies. More specifically, the exclusion 
criteria were: serological evidence of human immunodeficiency virus; ABO-incompatible 
grafts; patients with a history of malignant disorders; patients with severe diarrhoea, 
gastrointestinal disorders including active peptic ulcer disease and women who were 
pregnant, lactating or who were using inadequate contraception. Patients were also 
excluded if they had a white blood cell count of <2.5x10
3
/l, a platelet count of <100x10
3
/l 
or a haemoglobin concentration of <6g/dl at the time of randomisation.  
 
The trials all consisted of three arms: 
 conventional treatment, consisting of cyclosporin maintenance therapy in the European 
study and cyclosporin with azathioprine in the Tricontinental and US studies; 
 daily 2mg mycophenolate mofetil as an adjunct to cyclosporin therapy, but without the 
use of azathioprine; 
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 daily 3mg mycophenolate mofetil as an adjunct to cyclosporin therapy, but without the 
use of azathioprine. 
 
The primary outcome measure in all trials was the incidence of first biopsy proven acute 
rejection or treatment failure. Patient survival and graft loss were reported along with 
severity of acute rejection as secondary outcome measures. These primary outcome 
measures were all defined to be measured at the six month point in the individual trial 
designs, although the twelve month results are reported in the pooled analysis. 
 
The six month results for the individual trials are summarised in Table 2. The pooled 
analysis results at 12 months indicated that patient survival and graft survival were not 
statistically different from placebo or azathioprine treatment for either of the mycophenolate 
mofetil treatment arms. Strictly speaking, the pooled analysis should have undertaken a 
formal meta-analysis of the trials rather than simply pooling the results. The trials should 
have been tested for homogeneity and, only if this were proven, used a fixed or random 
effects model to combine the results. The biopsy proven acute rejection rates at 12 months 
were 40.8% for conventional treatment and 19.8% and 16.5% for the 2mg and 3mg 
mycophenolate mofetil treatment arms respectively. 
 
The absolute decrease in biopsy proven acute rejection was, therefore, in the range 20-
25%. This implies a NNT to avoid acute rejection in one patient of between four and five. 
  
As with tacrolimus, the severity of acute rejection episodes, in terms of both histological 
severity rating and resistance to corticosteroids, was reduced. The proportion of patients 
requiring anti-lymphocyte or monoclonal antibody therapy for steroid resistant rejection was 
19.7% in the conventional therapy population compared to 8.8% and 4.9% in the 2mg and 
3mg mycophenolate mofetil treated patients. 
 
The absolute decrease in steroid resistant rejection was, therefore, in the range 10-15%. 
This implies a NNT to avoid resistant rejection in one patient of between seven and ten. 
 
Three year follow-up studies of the Tricontinental and US mycophenolate mofetil trials have 
recently reported results (currently in abstract form): 
 
 The Tricontinental study
18
 reports that at three years mortality was comparable between 
all arms (mycophenolate mofetil 3g: 9.8%, mycophenolate mofetil 2g: 4.7%, azathioprine 
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: 8.6%). A marginal advantage in terms of graft and patient survival was found from 
mycophenolate mofetil treatment compared to conventional treatment (mycophenolate 
mofetil 3g: 84.8%, mycophenolate mofetil 2g: 81.9%, azathioprine : 80.2%). This 
marginal improvement was not statistically significant, though the study was neither 
designed nor powered to detect significant difference on graft survival at the three year 
time point. 
 
 Similarly, an intention to treat analysis of the US study
19
 data found no significant 
difference in: graft loss or death; graft loss only; graft loss due to rejection; or death, at 
either one year or three years, although it did find a marginal advantage in favour of 
mycophenolate mofetil. However, the study did not provide adequate statistical power to 
address these survival endpoints. 
 
2.3.2 Adverse Events and Contraindications Associated with Mycophenolate Mofetil  
 
Withdrawal due to adverse events and treatment failure was common throughout all 
treatment arms.  It should also be noted that the high level of withdrawal was reported in all 
trials. A pooled analysis of study withdrawal at 12 months showed that the withdrawal rates 
without prior biopsy proven rejection were 13.0%, 17.0% and 23.1% in the conventional, 
2mg and 3mg mycophenolate mofetil arms respectively. The proportion of patients 
withdrawing due to adverse events was higher in the two treatment arms than the 
conventionally treated arm and appeared to be dose related (5.2%, 8.7% and 14.7% 
respectively).  However, the proportion of patients withdrawing due to graft loss/death was 
marginally higher in the conventionally treated group than in the two treatment arms (3.4%, 
2.8% and 2.9%).  
 
Adverse events associated with mycophenolate mofetil treatment in the trial were: 
 increased gastrointestinal events, specifically vomiting, abdominal pain and diarrhoea; 
 increased leucopoenia and anaemia; 
 increased incidence of opportunistic infections. 
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Table 2 Randomised Controlled Trials Involving Mycophenolate Mofetil 
TRIAL EUROPEAN  MMF TRIAL
11
 US MMF TRIAL
12
 TRICONTINENTAL MMF TRIAL 
13
 
DESIGN Multi-centre, randomised, double-blind, placebo 
controlled 
Multi-centre, randomised, double-blind, controlled Multi-centre, randomised, double-blind, controlled 
PATIENT NUMBERS 491 (160 MMF3g,165 MMF2g, 166 placebo) 499 (166 MMF3g, 167 MMF2mg, 166 Azath.) 503 (164 MMF3g, 171 MMF2mg, 162 Azath.) 
INCLUSION CRITERIA age 181st/2nd renal allograft age 181st renal allograft age 181st/2nd renal allograft 
EXCLUSION CRITERIA History of malignant disorders, HIV+ive, HBsAG 
infection, gastrointestinal disorders, pregnant and 
lactating women, inadequate contraceptive methods 
Contraindication to cyclosporin, prednisone, 
azathioprine, ALG, unable to take oral medication, 
positive Tcell crossmatch. Pregnant women and 
men and women taking inadequate contraception 
methods. White blood cell count <2.5x10
3
/l, 
platelet count <100x10
3
/l, haemoglobin 
concentration <6g/dl,HIV-I or HTLV-I +ive, 
presence of HBsAg, active peptic ulcer disease, 
severe diarrhoea, current or historical malignancy. 
Unable to take oral medication, pregnant women 
and men and women taking inadequate 
contraception methods. Serological evidence of 
HIV+ive, HBsAG infection, active peptic ulcer 
disease, severe diarrhoea, gastrointestinal 
disorders, current or historical malignancy. 
STUDY PERIOD 6 months 3 years, interim results published at 6 months   3 years, interim results published at 6 months 
MEAN DAILY DOSE Cyclosporin dose ranged between 5 - 15 mg/kg  n/a Initially 8-10mg/kg, 6 months 3.7-4.0 mg/kg 
EFFICACY 
n 
Patient survival 
Graft survival 
Acute rejection 
Steroid resistance 
MMF3mg  
160 
156 (97.5%) 
146 (91.3%) 
22   (13.8%)
 *
 
 4      (2.5%) 
*
 [p<0.001] 
MMF2mg 
165  
161 (97.6%) 
154 (93.3%) 
28    (17.0%) 
*
 
5        (3.0%) 
Placebo 
166  
164 (98.8%) 
149 (89.8%) 
77   (46.4%) 
31   (18.7%) 
MMF3mg 
166  
157 (94.5%) 
152 (91.5%) 
29   (17.5%) 
6       (3.6%) 
MMF2mg 
165  
159(96.4%) 
156(94.5%) 
33
†
 (19.8%) 
13    (7.9%) 
†
 n=167 
Azathioprine 
164 
159 (97.0%) 
147 (89.4%) 
63   (38.0%) 
29   (17.7%) 
MMF3mg 
164  
157 (95.7%) 
146 (89.0%) 
26   (15.9%) 
5     (3.0%) 
 
MMF2mg 
171  
165 (96.5%) 
151 (88.3%) 
34
†
  (19.7%) 
12      (6.9%) 
†
n=173 
Azathioprine 
164 
155 (95.7%) 
140 (86.4%) 
59
†
 (35.5%) 
17   (10.2%) 
†
n=166 
WITHDRAWAL DUE TO 
ADVERSE EVENTS 
AND TREATMENT 
FAILURE 
56/160 (35.0%) 37/165 (22.4%) 58/166 (34.9%) 43/166 (25.9%) 35/165 (21.2%) 37/164 
(22.6%) 
42/164 (26%) 46/173 (27%) 50/166    
(30%) 
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Table 3 Summary of Acute Rejection Rates 
 
ACUTE REJECTION RATES 
(12 MONTHS) 
SYMPTOMATIC BIOPSY 
PROVEN 
BLINDED 
REVIEW 
CORTICOSTEROID 
RESISTANT 
HISTOLOGICALLY 
SEVERE 
CYCLOSPORIN European 
Tacrolimus 
54.4% 43.4% 35.9% 21.6% 6.2% 
 US 
Tacrolimus  
n/a 46.4% 44.4% 25.1% 4.3% 
 Pooled 
MMF trials  
49.0% 40.8% n/a 19.7% n/a 
TACROLIMUS European 
Tacrolimus 
32.3% 24.1% 17.5% 11.3% 2.6% 
 US 
Tacrolimus  
n/a 30.7% 27.8% 10.7% 2.0% 
MYCOPHENOLATE 
MOFETIL 
2mg MMF 
pooled 
29.7% 19.8% n/a 8.8% n/a 
 3mg MMF 
pooled 
25.1% 16.5% n/a 4.9% n/a 
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2.4 Neoral versus Sandimmun Formulations of Cyclosporin 
 
As highlighted by Moore,
20
 the control arms of the trials of tacrolimus and mycophenolate 
mofetil (MMF) in primary maintenance therapy all used the Sandimmun formulation of 
cyclosporin. This has recently been replaced by a new microemulsion cyclosporin 
formulation, Neoral. Improved effectiveness in preventing episodes of acute rejection is 
claimed for Neoral over Sandimmun, which will potentially affect the marginal effectiveness 
and cost-effectiveness of the other new drugs.  
 
A topic search for published trials of the Neoral formulation of cyclosporin versus the 
Sandimmun formulation, comparing the efficacy in preventing episodes of acute rejection, 
has identified three studies
21,22,23 
which compare primary maintenance for new transplant 
patients. The characteristics of these studies are detailed in Table 4. There exists further 
considerable literature on the conversion of existing transplant patients from Sandimmun to 
Neoral based maintenance therapy.  
 
Table 4  Trials of Neoral versus Sandimmun Formulations of Cyclosporin  
Trial Lodge JPA.
21
 Senel FM.
22
  Keown P.
23
 
Year (Publication) 1997 1997 1998 
Design Prospective, 
randomised, 
controlled, open 
label, multi-centre 
trial 
Non-randomised, 
consecutive case 
series comparison.  
Prospective, 
randomised, 
controlled, double 
blind, multi-centre 
trial 
Population 1
st
/2
nd
 cadaveric 
transplant recipients 
Consecutive renal 
transplant recipients 
1
st
/2
nd
 cadaveric 
transplant recipients 
Patient Numbers 288 143 167 
Duration 12 weeks interim, 
1 year 
1 year 3 months 
Efficacy outcomes Acute rejection, 
patient and graft 
survival.  
Acute rejection, 
patient and graft 
survival. 
Acute rejection, graft 
survival. 
 
 
Table 5 below, summarises the results of the Neoral versus Sandimmun trials and 
summarises the comparative Sandimmun results from the cyclosporin arms of the 
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tacrolimus and mycophenolate trials. Note that in all the trials considered, over 90% of acute 
rejection episodes in the first year occur in the first three month period, the different 
durations of the trials are, therefore, unlikely to be critical.  
 
Neoral is a microemulsion formulation of cyclosporin which gives improved absorption in 
comparison to the traditional oil-based oral Sandimmun formulation. Sandimmun, which has 
recently come out of patent, is no longer actively marketed by Novartis AG and is only 
available on request. This makes its use as a conventional treatment comparator in the 
evaluation prone to criticism. 
 
Trials have shown that it is possible to obtain higher trough blood levels at lower doses with 
Neoral and that these trough blood levels are obtained sooner than with Sandimmun. In the 
above trials, these benefits in cyclosporin absorption are claimed to give rise to the 
improvements in acute rejection rates. All trials monitored adverse events and particularly 
those known to be associated with cyclosporin; none of the above trials found an increase. 
 
 
Table 5 Suspected Acute Rejection Rates Associated with Neoral or Sandimmun 
Primary Maintenance Therapy 
Source n  (Neoral: 
Sandimmun) 
Period Sandimmun Neoral % Relative 
reduction in 
acute rejection 
rate 
Lodge
21
 288 (2:1) 12 
weeks 
54.6% 41.4% 24% 
Senel
22
 143 (40:103) 12 
months 
57% 49% 14% 
Keown
23
 167 (1:1) 3 
months 
60.5% 44.2% 27% 
Tacrolimus 
trials  
 12 
months 
54.4% --  
MMF trials   12 
months 
49.0% --  
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These results imply that the clinical benefit of both tacrolimus and mycophenolate mofetil 
over Sandimmun may be less than any clinical benefit over Neoral. The cost of Neoral is 
similar to the cost of Sandimmun and, therefore, the marginal cost-effectiveness of 
tacrolimus and mycophenolate mofetil is likely to be adversely affected. In order to estimate 
this marginal effectivenes (and marginal cost-effectiveness), it is necessary to construct 
synthetic comparisons between tacrolimus and Neoral, and between mycophenolate mofetil 
and Neoral.    
 
In order to generate the required synthetic comparisons an adjustment in acute rejection 
rates obtained by replacing Neoral for Sandimmun in the appropriate trials is required. The 
problem is to obtain a justifiable adjustment factor. 
    
It should be noted that the acute rejection rates achieved in any of the trials are related to 
doses used and to the prognostic characteristics of the trial populations. This makes the 
comparison between trials very difficult. The suspected acute rejection rates for the 
Sandimmun arms of the Sandimmun versus Neoral trials ranged from 55% to 61%, whilst 
the Sandimmun arms of the tacrolimus and mycophenolate mofetil trials ranged from 49% 
to 55%, that is consistently lower. Thus, assuming that the use of Neoral would have given 
rise to even lower rates of suspected acute rejection may give misleading results. 
 
2.5 Conclusion on Direction of Evidence and its Quality 
 
The published trials provide strong evidence that either replacing cyclosporin with tacrolimus 
in the maintenance immunosuppression regimen or prescribing mycophenolate mofetil as 
an adjunct to cyclosporin, decreases the incidence of episodes of acute rejection in the first 
year after transplantation in comparison to the Sandimmun formulation of cyclosporin. 
 
There is also strong evidence that the severity of episodes of acute rejection is significantly 
reduced under both the tacrolimus and mycophenolate mofetil regimens. This improvement 
is apparent both in terms of episodes classified as histologically severe and in terms of 
patients requiring anti-lymphocyte antibody or monoclonal antibody treatment for 
corticosteroid resistant acute rejection. 
 
Patient death and graft loss in the first year after transplantation under conventional 
immunosuppressant maintenance and rescue therapy is rare. The evidence from the 
published trials is that patient survival and graft survival for the new tacrolimus and 
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mycophenolate mofetil treatments are comparable to conventional therapy.  No statistically 
significant differences in patient death or graft loss were found in any of the analysed trials. 
 
Withdrawal rates were high in all studies. Furthermore, the incidence of withdrawal due to 
adverse events was higher in the treatment arms for both tacrolimus and mycophenolate 
mofetil than in the conventional treatment arms. In the case of tacrolimus, treatment was 
associated with increased renal, neurological and cardiovascular complications. 
Mycophenolate mofetil was associated with increased levels of gastrointestinal 
complications and opportunistic infections, and withdrawal due to adverse events appeared 
to be dose related. 
 
There is some evidence that the microemulsion formulation of cyclosporin, that replaces 
Sandimmun, improves control of acute rejection. Whilst this may potentially reduce the 
marginal effectiveness of tacrolimus and mycophenolate mofetil, and it is possible to 
estimate the potential magnitude of this bias, this inevitably introduces a new layer of 
uncertainty into the comparisons. 
 
Episodes of acute rejection are one of the most important prognostic indicators for later 
chronic rejection and consequential graft loss.
24,25,26,27,28
 This fact provides a logical basis for 
the conjecture that a reduction in the incidence of acute rejection, in the period following 
transplantation, will lead to a corresponding reduction in long-term graft loss. If this 
conjecture were proven, then it would be an important outcome of any new maintenance 
strategy. The currently published trials of the new therapies, however, were not designed to 
address the long-term outcomes related to graft loss. There is, therefore, no significant 
direct evidence concerning the effects of the new agents on long-term graft survival. 
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3. COST AND BENEFIT IMPLICATIONS OF NEW IMMUNOSUPPRESSANT 
MAINTENANCE STRATEGIES FOR RENAL TRANSPLANTATION  
 
3.1 Analytical Overview 
 
Two new immunosuppressant maintenance strategies are evaluated in comparison to a 
conventional maintenance strategy which reflects most common current practice. 
 
 Tacrolimus   Maintenance immunosuppression with tacrolimus, 
 azathioprine and prednisolone;   
 Mycophenolate mofetil  Maintenance immunosuppression with  
 cyclosporin, mycophenolate mofetil and prednisolone; 
 Conventional  Maintenance immunosuppression with cyclosporin,  
 azathioprine and prednisolone.  
 
The immunosuppressive agents tacrolimus and mycophenolate mofetil are more expensive 
than the agents they replace. The annual drug costs associated with the two new 
maintenance strategies are, therefore, higher than for conventional maintenance therapy.  
 
The potential benefits to be gained from the adoption of the new interventions are: 
 
 avoidance of episodes of acute rejection, leading to improved quality of life; 
 reduction in the severity of episodes of acute rejection, again leading to improved quality 
of life; 
 reduced costs associated with treatment of acute rejection including reduced costs of 
treating severe or corticosteroid resistant rejection; 
 possible reduction in later chronic rejection and graft failure related to reduced acute 
rejection; 
 possible reduction in the costs associated with treating chronic rejection and graft 
failure; 
 possible reduction in indirect costs arising from graft failure, for instance, 
retransplantation and dialysis; 
 possible increase in the expected life of renal transplants which would lead to a 
decrease in the demand for retransplantation and a consequential increase in the 
availability of transplantation for new and waiting patients.  
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The large majority of episodes of acute rejection occur within six months of transplantation. 
The Halloran pooled analysis
17
 of mycophenolate mofetil showed that approximately 99% of 
episodes within the first year occurred within the first six months. The currently available 
RCTs concerning the new agents provide strong evidence about their health benefits in 
relation to early episodes of acute rejection. Therefore, the cost and benefits of treatment 
over the first year of treatment after transplantation based on this trial evidence can be 
evaluated. The costs of treatment used in the analysis are summarised in Section 3.2 and 
the short-term marginal costs of treatment are estimated in Section 3.3 .  
 
The published evidence
24-28
 concerning prognostic factors for chronic rejection identifies 
episodes of acute rejection as a major risk factor. This provides a theoretical basis for the 
proposition that the new agents may provide a long-term benefit in terms of reduction in 
chronic rejection and graft loss. There is, however, little RCT evidence concerning the 
possible long-term benefits in terms of avoidance of chronic rejection or graft loss. There is, 
therefore, a much greater level of uncertainty concerning the potential costs and 
consequences of long-term usage of the new agents; this is explored in Section 3.4. 
 
The RCTs of the new agents all use a formulation of cyclosporin that has since been 
superseded. There is some evidence that the new microemulsion formulation of cyclosporin 
provides greater control of acute rejection than the older formulation. The evidence for this 
benefit is summarised in Section 3.5 and the potential effect on the marginal costs and 
benefits of the new agents over the first year post transplant is explored. 
   
3.2 Costs of Treatment 
 
3.2.1 Costs Included in the Evaluation 
 
This evaluation uses a health service perspective in relation to costs. Indirect costs, such 
as, societal costs and costs to the patient due to episodes of acute rejection have not been 
included. The new treatments might be expected to reduce indirect costs by reducing the 
support required by patients during episodes of acute rejection. Not including these costs, 
therefore, favours conventional therapy in this evaluation. 
 
The available evidence shows no significant difference between the treatments in patient 
death and graft loss in the first year after transplantation and, moreover, does not address 
these outcomes in the longer-term. This comparative evaluation, therefore, excludes costs 
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associated with these events. In the short-term, one year evaluation, these costs are 
expected to be similar between treatments. In the longer-term, on the assumption that long-
term chronic rejection rates are reduced, ignoring costs associated with these events will 
favour the conventional therapy in this evaluation.  
 
The costs associated with treatment and considered in this model, can be broken down into: 
 cost of maintenance immunosuppressant drugs; 
 cost of treating corticosteroid responsive acute rejection; 
 cost of treating corticosteroid resistant acute rejection. 
 
3.2.2 Cost of Maintenance Immunosuppressant Drugs 
 
For both the cyclosporin and tacrolimus treatments, elevated doses are required in the high 
risk period following transplantation. The maintenance drug costs are, therefore, broken 
down into ‘Initial 3 Month Period’ costs and ‘Steady State’ costs. 
 
Where drug dosages are specified in terms of mg/kg, an average adult body mass of 77kg 
has been used to calculate average daily dosages, this average body mass was provided by 
the Nottingham City Hospital Renal Pharmacy Unit. The cost of drugs has been taken from 
the charged prices incurred by the Nottingham City Hospital Renal Pharmacy Unit. Table 6 
shows the quarterly maintenance drug dosages and costs based upon these assumptions. 
 
Table 6 Maintenance Drug Dosages and Costs 
Daily dose Daily Quarterly Annual
(mg/kg/day) Cost Cost Cost
Cyclosporin Initial 3 months 7 £13.37 £1,220
(Sandimmun) Steady state 4 £7.64 £697 £3,313
Tacrolimus Initial 3 months 0.15 £21.85 £1,994
(Prograf) Steady state 0.075 £10.92 £997 £4,984
Cyclosporin & Cyc. initial 7 £13.37 £1,220
Mycophenolate MMF initial 2mg total £10.60 £968
mofetil (Cellcept) Total £2,188
Cyc. steady state 4 £7.64 £697
MMF steady state 2mg total £10.60 £968
Total £1,665 £7,183
Note: The above excludes the costs associated with prednisolone and azathioprine, as both of these drugs are 
of negligible cost relative to cyclosporin, tacrolimus and mycophenolate mofetil. 
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3.2.3 Cost of Treating Acute Rejection 
 
Where symptoms of acute rejection occur, a number of diagnostic tests are undertaken. 
The evaluation only includes diagnostic costs as an element of acute rejection costs; no 
account is taken of diagnostic costs which do not lead to acute rejection being identified. 
 
The standard treatment for acute rejection is intravenous methylprednisolone given as an 
out-patient on three consecutive days. 
 
If the acute rejection is resistant to corticosteroid treatment then polyclonal antibodies, anti-
thymocyte globulin (ATG) or anti-lymphocyte globulin (ALG), or monoclonal antibodies 
(OKT3) are given. At Nottingham City Hospital this therapy would usually take place within 
the hospital and involve an in-patient stay in a high dependency ward of between 10 and 14 
days. 
 
The costs associated with acute rejection are: 
 cost of diagnosis; 
 cost of treating corticosteroid responsive acute rejection; 
 cost of treating corticosteroid resistant acute rejection. 
 
These are detailed further below:  
 
Cost of diagnosis: 
 
Renal biopsy £180.00 
Blood tests £ 50.00 
Ultrasound scan £  45.00 
Total diagnostic costs £275.00 
 
This does not include costs associated with in-patient or day case admissions or out-
patient attendances for diagnostic procedures. It is, therefore, an underestimate of the total 
cost. 
 
  28 
Cost of treating corticosteroid responsive acute rejection: 
 
The cost of an out-patient attendance is available from the routine hospital returns (TFR2). 
The average cost in 1994/95 of attendance at a renal transplant out-patient clinic at 
Nottingham City Hospital was £83.36; between three and five out-patient attendances are 
normally required. 
 
Table 7 Costs of Treating Corticosteroid Responsive Acute Rejection 
Drug Infusion 
Dose 
Infusion 
Cost 
Out-patient 
Attendance 
Infusions Total 
Cost 
Methylprednisolone 500mg £2.74 £83.36 3 £258.30 
 
Cost of treating corticosteroid resistant acute rejection: 
 
A 14 day in-patient stay cost is estimated at: 
High dependency ward @ £350 per day : £4,900 
  
A number of different treatments are available for the treatment of corticosteroid resistant 
rejection. These are the polyclonal antibodies, ATG and anti-lymphocyte globulin (ALG) and 
OKT3. The dosages, treatment regimen and costs are detailed in Table 8. Of these 
therapies ATG is the most commonly used treatment. 
 
Table 8 Cost of Drugs for Treating Steroid Resistant Acute Rejection 
Drug Infusion 
Dose 
Infusion 
Cost  
Infusions  Total Drug 
Cost 
ATG 154 mg £347.42 7 £2,432 
ALG 770 mg £380.00 14 £5,320 
OKT3 5 ml £440.45 14 £6,166 
 
  29 
3.3 One Year Cost and Consequences Analysis 
 
Table 9 summarises the expected number and severity of episodes of acute rejection in 13 
new transplants, being the annual number of transplants undertaken from a 'typical' district 
population of 500,000 under the maintenance strategies considered. These estimates are 
based on trial comparisons of tacrolimus and mycophenolate mofetil with a conventional 
therapy based on the Sandimmun formulation of cyclosporin. 
 
Table 10 summarises the expected costs associated with the treatment strategies on a per 
patient basis and for 13 new transplant patients. 
 
The published Kaplan-Meier estimates of acute rejection rates relate to the first episode of  
rejection. For the purposes of this evaluation, it has been assumed that the incidence of 
further episodes of rejection follow a similar distribution to the first episode. The expected 
number of episodes of rejection in the first year is greater, therefore, than the base rejection 
rates quoted in the published trials. For example, for cyclosporin the 12 month biopsy 
proven rejection rate from the pooling of all trials is approximately 45% (c.f. European 
Tacrolimus
9
  trial at 12 months is 43%), however, based on this assumption, the expected 
number of rejection episodes for an individual in the first year is 0.78 not 0.45. The numbers 
of patients with 0,1,2,3 and  4 episodes of rejection obtained from this model of multiple 
episodes has been validated against the corresponding numbers of patients at Nottingham 
City Hospital under cyclosporin maintenance therapy. 
 
The costs of treating corticosteroid resistant acute rejection are based on the use of ATG, 
which is the preferred antibody regimen at Nottingham City Hospital, and one of the primary 
resistant rescue regimens used in the trials. A hospital stay of 14 days in a high dependency 
ward is appropriate with this use of ATG as the more intensive monitoring (specifically of 
CD3 count) allows lower dosages to be used, thus avoiding over immunosuppression. 
 
Although hospital stays constitute a major resource use in the treatment of acute rejection, 
the savings associated with a reduction in total bed usage may not be directly realisable 
unless the reduction is sufficient either to allow a reduction in capacity or to allow capacity to 
be used in the treatment of other patients. 
 
The average cost of acute rejection per patient given below is calculated from the expected 
cost per episode multiplied by the expected number of episodes per patient. 
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Table 9  Summary of Acute Rejection Episodes in an Annual District Transplant 
Population  
Maintenance Expected Number of  Episodes
Strategy of Acute Rejection Rrange)
Responsive Resistant Total
Tacrolimus 2.9 (2.4, 3.5) 1.8 (1.5, 2.2) 4.7 (3.9, 5.7)
MMF 2mg 1.8 (1.4, 2.2) 1.4 (1.1, 1.7) 3.3 (2.5, 3.9)
Cyclosporin 
(Sandimmun) 4.7 (4.2, 5.2) 4.5 (4.0, 5.0) 9.2 (8.1, 10.2)
Tacrolimus vs 
Cyclosporin 
(Sandimmun) -1.8 (-2.9, -0.7) -2.7 (-3.5, -1.8) -4.4 (-6.4, -2.5)
MMF vs 
Cyclopsorin 
(Sandimmun) -2.9 (-3.8, -2.0) -3.1 (-3.9, -2.3) -5.9 (-7.7, -4.3)
 
 
 
Table 10 Summary of Patient and Population First Year Costs for Maintenance 
Strategies 
Maintenance Cost of Acute Rejection Per Patient Cost of Total Cost Total Cost
Strategy Responsive Resistant Rejection Maintenance per Patient 13 Patients
Rejection Drugs and 
diagnosis In-patient
per Patient
Tacrolimus £118 £383 £694 £4,890 £6,086 £79,119
MMF 2mg £75 £298 £540 £7,105 £8,017 £104,226
Cyclosporin 
(Sandimmun) £192 £936 £1,694 £3,204 £6,026 £78,332
Tacrolimus vs -£74 -£552 -£1000 £1,686 £61 £787
Cyclosporin 
(Sandimmun)
(-£117, -£29) (-£730, -£375) (-£1321, -£680)(£1658, £1713) (-£454, £574) (-£5902, £7459)
MMF vs -£117 -£637 -£1154 £3900 £1,992 £25,895
Cyclosporin 
(Sandimmun)
(-£156, -£83) (-£812, -£483) (-£1470, -£875)(£3876, £3929) (£1492, £2435) (£19391, £31649)
 
The trials all show a remarkable consistency in the rates of acute rejection achieved, see 
Table 3, for each of the maintenance strategies. The above estimates are based upon 
pooled acute rejection rates for cyclosporin, tacrolimus and mycophenolate mofetil 
respectively. A sensitivity analysis for the total cost of treatment based upon the maximum 
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and minimum advantage in terms of acute rejection rates shown in the trials is presented in 
Table 11. The maximum advantage is derived from the highest rejection rate (that is the 
upper 95% confidence limit) for cyclosporin treatment and the lowest rate (that is the lower 
confidence limit) for tacrolimus or mycophenolate mofetil. The minimum advantage is 
derived from the lowest rejection rate for cyclosporin and the highest rejection rates for the 
new treatments.  
 
Table 11  Sensitivity of Total Cost Per Patient to Error in Acute Rejection Rates  
Maintenance Strategy Minimum 
Advantage 
Central 
Estimate 
Maximum 
Advantage 
Tacrolimus vs Cyclosporin 
(Sandimmun) 
£574 £61 -£454 
MMF vs Cyclosporin 
(Sandimmun) 
£2,435 £1,992 £1,492 
 
 
3.4 Long-term Cost and Consequences Analysis 
 
The one year post-transplant analysis detailed in Section 3.3 identifies the potential for cost 
savings arising in the first year. These cost savings arise from a reduction in the number 
and severity of acute rejection episodes which offset the increase in maintenance therapy 
costs. If graft survival to one year is achieved, then the risk of further episodes of acute 
rejection is much reduced. Therefore, the full increase in maintenance costs is likely to be 
borne for patients after the initial year post transplantation. 
 
Table 10 shows the average cost per year of maintenance therapy once a steady state has 
been achieved. In conventional therapy, most UK centres would give a mean dose of 
4mg/kg/day of cyclosporin to maintain a therapeutic level of 100-200ng/ml. In the tacrolimus 
clinical trials already analysed, an initial dose of 0.15mg/kg/day was given which resulted in 
a significant number of withdrawals due to side-effects. These side-effects are dose 
dependent and it has been recommended subsequently that the dose of tacrolimus should 
be titrated against response and side-effects. Once a steady state has been achieved, 
usually within three months, 0.05-0.075mg/kg/day in a divided dose can be given. In 
practice, an equal dose is given twice daily to fall within that window. Thus an 85kg patient 
will receive 3mg twice daily (0.071mg/kg/day) rather than 2mg twice daily (0.047mg/kg/day), 
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whereas a 72kg patient will receive 2mg twice daily (0.055mg/kg/day) rather than 3mg twice 
daily (0.083mg/kg/day).  
 
There has been some early work, as yet unpublished, showing that mycophenolate mofetil 
can be given safely with a dose of cyclosporin of 2.5mg/kg/day in stable patients. This 
likewise would reduce the cost difference when compared to conventional therapy. 
 
The cost per year of maintenance with immunosuppressive drugs after the first year is 
calculated from the steady state dosages for the three management strategies considered 
and is very sensitive to the mean dosages achieved. At Nottingham City Hospital the current 
target steady state dosage for tacrolimus is 0.05 - 0.075 mg/kg; where this is achieved the 
annual steady state cost for tacrolimus would be £2,660 - £3,390.  Note that in the case of 
child transplant patients the dosages, and hence maintenance costs, are likely to be 
markedly less than in the adult population. 
 
Table 12 Cost Per Year of Maintenance Therapy at Steady State Dosage 
Maintenance Strategy Mean Daily 
Dose  
Annual Cost per 
Patient  
Difference 
 
Cyclosporin (Sandimmun)  4 mg/kg £2,790 --        
Tacrolimus  0.075 mg/kg £3,990 £1,200 
Cyclosporin (Sandimmun)  
& Mycophenolate mofetil  
 4 mg/kg 
 2 mg 
 
£6,660 
 
£3,870 
 
 
As highlighted in Section 3.1, the occurrence of severe, multiple and late episodes of acute 
rejection are all risk factors for the development of chronic rejection and consequent 
reduced graft survival.  It can be hypothesised that, by reducing both the number and 
severity of acute rejection episodes using tacrolimus and mycophenolate mofetil based 
regimens, the onset of chronic rejection and subsequent graft loss may be prevented or 
delayed. 
 
A long-term cyclosporin dose-ranging study involving both cadaveric and living donor 
transplants
28
  identified a five year graft survival rate of 68.7% in patients who had no history 
of acute rejection compared with 42.9% in patients who had experienced acute rejection. If 
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these five year survival rates are applied to the trial populations considered in Section 3.3, 
the reduction in first year biopsy proven acute rejection from approximately 43% for 
cyclosporin to 28% for tacrolimus treatment would imply a 4% improvement in graft survival 
at five years. Similarly, the figures for mycophenolate mofetil would imply a 6% improvement 
in five year graft survival. 
  
It should be noted that these figures are consistent with the three year graft survival 
improvement reported in the abstract
19
  from the US mycophenolate mofetil study. This 
study reported a 6% improvement in patient/graft survival for mycophenolate mofetil 2mg 
treatment compared to cyclosporin with azathioprine treatment, although this improvement 
was not statistically significant, Table 12 refers. 
 
Table 13 Long-term Results from US Mycophenolate Mofetil Trial 
Intention to Treat Analysis at 3 Years 
 MMF 2mg MMF 3mg Azathioprine p 
Graft 
loss/death  
18.8% 21.7% 25.0% not significant 
Graft loss only 12.7% 15.7% 16.5% not significant 
Graft loss due 
to rejection 
10.3% 10.2% 12.8% not significant 
Death 10.3% 12.0% 11.6% not significant 
 
 
Thus, an estimate of the additional cost per graft loss or death avoided can be obtained and 
is outlined in Table 14. The figures will be over-estimates as they are based on treatment for 
the full three years for all patients, i.e. treatment failures leading to switching or cessation of 
drug regimens prior to three years or deaths are not accounted for. 
 
Although long-term use of the new regimens has an increased cost, this would be offset to 
some extent, by reducing the costs associated with graft failure. These would include 
avoidance of dialysis, estimated at £17,800 per year and avoidance of the higher treatment 
costs associated with re-transplantation and treatment during the first year after re-
transplantation. The cost of a failed transplant has been estimated at approximately £94,000 
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per patient per year, including not only the costs associated with the recipient (extra 
immunosuppressive therapy, resumption of dialysis and continuation of dialysis), but also 
those from the denial of that kidney for another dialysis dependent patient in whom it may 
have worked better.
29
  
Table 14  Additional Maintenance Drug Costs in Years 2 and 3 per Graft Loss 
Avoided 
 Improvement in 
Graft/ 
Patient Survival  
Number Needed 
to Treat 
Additional Cost 
per Patient Year in 
Years 2 and 3 
Cost per Graft 
Loss/ Patient 
Death Avoided 
Tacrolimus 4% 25 £1,200 £30,000 
Cyclosporin & 
Mycophenolate 
mofetil 2mg 
6% 17 £3,870 £64,500 
 
 
Since these agents are more potent immunosuppressants their long-term use may allow the 
cessation of steroids and reduction of the cyclosporin dose.  Tacrolimus could be given as 
monotherapy and mycophenolate mofetil with a reduced cyclosporin dosage (2mg/kg/day).  
The potential steroid sparing effect of both of these regimens should have a significant 
effect upon long-term morbidity e.g. cataracts and bone problems.  Likewise, lower doses of 
cyclosporin reduce the risk of chronic cyclosporin nephrotoxicity. 
 
3.5 Potential Impact of Replacing Sandimmun with Neoral on the Marginal Cost 
and Marginal Effectiveness of Tacrolimus and Mycophenolate Mofetil 
 
The trials of tacrolimus and mycophenolate mofetil in primary maintenance therapy all used 
the Sandimmun formulation of cyclosporin. This has recently been replaced by a new 
microemulsion cyclosporin formulation, Neoral. The improved clinical effectiveness of Neoral 
in comparison to Sandimmun is discussed in Section 2.4. The potential impact on the 
marginal cost-effectiveness of tacrolimus and mycophenolate mofetil is investigated here.  
 
Table 15 summarises the potential clinical impact of using Neoral in place of Sandimmun. 
The most favourable assumptions for Neoral (and conversely the most conservative 
assumptions for tacrolimus and mycophenolate mofetil) are considered, that is that Neoral 
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imparts a 25% advantage in terms of acute rejections avoided over Sandimmun. If Neoral 
imparts no benefit over Sandimmun the marginal cost-effectiveness is as previously 
analysed. 
 
Table 15  Summary of Acute Rejection Episodes in a 'Typical' District Transplant 
Population of 13 Patients 
Maintenance Expected Number of Episodes
Strategy of Acute Rejection (Range)
Responsive Resistant Total
Tacrolimus 2.9 1.8 4.7
MMF 2mg 1.8 1.4 3.3
Cyclosporin 
(Sandimmun) 4.7 4.5 9.2
Tacrolimus vs 
Cyclosporin 
(Sandimmun) -1.8 -2.7 -4.4
MMF vs 
Cyclosporin 
(Sandimmun) -2.9 -3.1 -5.9
Cyclosporin 
(Neoral) 3.1 3.0 6.1
Tacrolimus vs 
Cyclosporin 
(Neoral) -0.2 -1.2 -1.4
MMF vs 
Cyclosporin 
(Neoral) -1.3 -1.6 -2.9  
Note: mycophenolate mofetil here indicates a combination therapy using mycophenolate mofetil with cyclosporin 
as compared with cyclosporin alone. 
 
 
Under the most extreme assumption in terms of benefit from Neoral therapy, it can be seen 
that the advantage of tacrolimus over Sandimmun is reduced from 4.4 to 1.4 episodes of 
acute rejection in an annual district population of 13 new transplant patients in their first 
year. Similarly, the advantage of mycophenolate mofetil is reduced from 5.9 episodes to 2.9 
episodes. 
 
Given the uncertainty concerning the actual benefit achieved from Neoral relative to 
Sandimmun, and uncertainty as to whether this benefit would be seen in head to head trials 
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against tacrolimus or mycophenolate mofetil, the other extreme estimate must be that the 
marginal cost and marginal effectiveness would be as previously estimated. 
  
Furthermore, mycophenolate mofetil is given in addition to cyclosporin and has a very 
distinct mode of action, therefore, it may be argued that the marginal effectiveness of 
mycophenolate mofetil plus Sandimmun over Sandimmun alone may be similar to the 
marginal effectiveness of mycophenolate mofetil plus Neoral over Neoral alone. In this case 
the marginal cost-effectiveness would be similar to the estimates previously obtained.  
 
Table 16 summarises the first year costs associated with use of Neoral in place in 
Sandimmun.  
 
Table 16  Summary of Patient and Population First Year Costs for Maintenance 
Strategies 
Strategy Responsive Resistant Rejection Maintenance Total cost Total cost
Rejection Drugs and 
Diagnosis Inpatient
per Patient per Patient 13 Patients
Tacrolimus £118 £383 £694 £4,890 £6,086 £79,119
MMF 2mg £75 £298 £540 £7,105 £8,017 £104,226
Cyclosporin 
(Sandimmun) £192 £936 £1,694 £3,204 £6,026 £78,332
Tacrolimus vs -£74 -£552 £1000 £1686 £61 £787
Cyclosporin 
(Sandimmun)
MMF vs -£117 -£637 -£1154 £3900 £1,992 £25,895
Cyclosprorin 
(Sandimmun)
Cyclosporin 
(Neoral) £128 £625 £1,131 £3,237 £5,122 £66,582
Tacrolimus vs 
Cyclosporin 
(Neoral) -£10 -£241 -£437 £1,653 £964 £12,537
MMF vs 
Cyclosporin 
(Neoral) -£53 -£327 -£591 £3,867 £2,896 £37,644
Note: mycophenolate mofetil here indicates a combination of therapy using mycophenolate mofetil with 
cyclosporin as compared with cyclosporin alone. 
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Under the most extreme assumption in terms of benefit from Neoral therapy, it can be seen 
that, whereas tacrolimus was estimated to be approximately cost neutral over Sandimmun 
(difference of £61 per patient) in the first year, over Neoral the cost difference would be 
approximately £1,000 per patient. Similarly, for mycophenolate mofetil the cost difference 
has risen from approximately £2,000 to nearly £3,000 per patient in the first year. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
The options available depend on whether purchasers wish to specify the use of a particular 
drug in their service agreements. Service agreements often specify the number of patients 
on dialysis, by type of dialysis, and the number of ‘new’, that is within one year of a 
transplant, and ‘old’ transplant patients.  An agreement of this type enables any drug to be 
introduced at the discretion of the clinician, if there is no resulting change in the overall cost 
of treating patients in that particular category.  This can be achieved either if the drug is the 
same price as the previous treatment or if the hospital can make compensatory savings in 
another part of the service.  The impact of the new drugs available for reducing the risk of 
rejection is, however, likely to raise the costs per case within the hospital budget, not only 
due to the cost of the individual drugs, but also because these drugs will be perceived as 
less suitable for prescription in general practice.  
 
Purchasers could insist that, if the drugs are seen to be effective, their use should be 
prioritised within the unit, at the expense of other, possibly less well researched, treatments 
or procedures. 
 
Within a renal unit the options are: 
 to continue to use conventional treatment as previously; 
 to use tacrolimus, for either all or selected patients; 
 to use mycophenolate mofetil, for either all or selected patients; or 
 to use both mycophenolate mofetil and tacrolimus for appropriate patients. 
 
Given the lack of information on risks of infectious complications and malignancy associated 
with the long-term use of the two new agents, it may be appropriate to implement initially the 
new agents as primary maintenance in immunologically high risk patients whilst using 
conventional primary maintenance therapy for immunologically low risk patients. 
 
The definition of high risk used at the Nottingham Renal Unit is:  
 loss of previous transplant to acute rejection; 
 the presence of >50% cytotoxic antibodies in current or historic serum; 
 third or subsequent transplant; 
 1 or 2 DR mismatch. 
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On this basis, for the calendar years 1997 and 1998, the Nottingham unit performed 81 
adult renal transplants. Using the above criteria 30% of transplants were on immunologically 
high risk patients. 
 
Over the same period, 34% of newly transplanted patients had at least one episode of 
rejection in the first three months post-transplant. 40% of these patients experiencing 
rejection had steroid resistant rejection and were given tacrolimus rescue therapy.  
 
In the immunologically high risk group, 41% had at least one episode of rejection in the first 
three months post-transplant, of which 56% were steroid resistant. In the immunologically 
normal risk group, 31% had at least one episode of rejection in the first three months, of 
which 31% were steroid resistant. 
 
In corroboration of the earlier analysis, the incidence of acute rejection has been lower in 
the Nottingham Renal Unit patients since the beginning of 1997 when the 
immunosuppressive policy was altered to Neoral (7mg/kg/day), azathioprine (1.5mg/kg/day) 
and prednisolone (20mg) as initial therapy. Before that, the acute rejection rate was nearer 
to 50%. 
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5. DISCUSSION AND CONCLUSIONS 
 
The clinical trial evidence demonstrates that immunosuppressive regimens containing 
tacrolimus or mycophenolate mofetil significantly reduce the incidence and severity of acute 
rejection within the first year post-transplantation. These studies were neither designed nor 
powered to demonstrate long-term improvements in graft survival; in fact studies with very 
large numbers of patients would be required and these are not realistic. Many studies have 
shown, however, that the number and severity of acute rejection episodes correlates with 
the development of chronic rejection, which will, therefore, influence graft survival and 
subsequent return to dialysis. 
 
In demonstrating the cost and consequences of using tacrolimus and mycophenolate mofetil 
in the first year following transplantation, certain caveats have to be made.  Within the UK 
healthcare system reduced in-patient bed stay and staff costs do not translate easily to real 
cost savings.  This would not be the case in insurance funded health schemes where every 
part of the process may be individually costed and paid for separately. 
 
It becomes even more difficult in realising long-term cost savings, which may be intangible.  
These include the positive clinical and economic benefits of prolonged graft survival.  If the 
graft is functioning well, fewer out-patient visits and diagnostic tests/procedures are 
required, and the patient can live with a good quality of life and with good occupational 
rehabilitation. Poor transplant function with chronic rejection results in more clinic visits, 
more diagnostic tests/procedures, and the inevitable need for dialysis and re-
transplantation. A failed transplant is very expensive and has been calculated by others at 
£94,000 per patient per year, which includes not only the costs associated with the recipient 
(extra immunosuppressive therapy, resumption of dialysis and continuation of dialysis), but 
also the denial of that kidney for another dialysis dependent patient in whom it may have 
worked better.
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 Therefore, long-term graft survival is one of the primary aims of 
transplantation and meeting this goal can be helped by effective immunosuppressive 
protocols alongside other strategies to reduce morbidity. 
 
As discussed in Section 3.4 there are also other long-term cost savings which are difficult to 
measure accruing from steroid-sparing immunosuppressive protocols.  This possibility is 
more likely with tacrolimus and mycophenolate mofetil regimens where there has been less 
rejection and, therefore, less need for long-term steroid therapy.  The use of steroids long-
term is undoubtedly associated with increased morbidity which includes bone problems 
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(osteopoenia, fractures, avascular necrosis) and cataracts.  Prednisolone and azathioprine 
have been used for over 30 years in clinical transplantation and, as such, are cheap, so 
there are few direct cost savings to be made.  Savings come from the associated reduced 
morbidity. 
 
It is known that there is an increased risk of acute rejection in the first six months post-
transplantation and that the incidence after one year is low.  It can be argued that more 
potent immunosuppression should be given to cover this high risk period with conversion to 
conventional treatment thereafter. Thus, the extra costs of tacrolimus or mycophenolate 
mofetil would be concentrated in the first year. There is as yet no published evidence 
looking at  conversion from tacrolimus or mycophenolate mofetil. 
 
There are now recognised guidelines for converting patients from tacrolimus to cyclosporin 
which are safe, but, as with any change of immunosuppression, it could precipitate an 
episode of acute rejection.  There are also issues of patient compliance: tacrolimus is a 
small tablet whereas cyclosporin is relatively large, and if patients are stable on one drug 
they may be reluctant to change.  Likewise, it would be straightforward to convert patients 
from mycophenolate mofetil to azathioprine with consequent cost savings; because the 
patient would still be receiving cyclosporin, the risk of rejection would be low. 
 
Conversions as described above should be safe where: 
 graft function is stable; 
 the patient is immunologically low risk (good HLA match with low cytotoxic antibodies); 
 the patient has had little or no rejection. 
 
However, where these criteria are not met, there would be an increased risk of acute 
rejection associated with conversion. 
 
When the new agents are compared with the Sandimmun formulation of cyclosporin, 
tacrolimus is estimated to be potentially cost neutral and result in an average of 4.4 
episodes of acute rejection avoided per annum in a 'typical' health authority. Similarly, 
mycophenolate mofetil was shown to have an additional cost of £26,000 (£19,000-£32,000) 
per year and result in an average of 5.9 episodes of acute rejection avoided per annum in a 
'typical' health authority. 
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Revising the estimates to take account of the improved performance of the Neoral 
formulation of cyclosporin compared with Sandimmun produces a reduced estimate of 
marginal benefit for both tacrolimus and mycophenolate mofetil. Accordingly, tacrolimus is 
no longer cost neutral, but would be estimated to cost approximately £12,500 more per 
annum and prevent an average of only 1.4 episode of acute rejection in a 'typical' health 
authority. Estimating the marginal effect for mycophenolate mofetil is more difficult since 
mycophenolate mofetil is used in addition to cyclosporin. The marginal cost-effectiveness 
may remain as estimated earlier, or reduce further to an extra cost of £37,600 together with 
only 2.9 episodes of acute rejections avoided per annum.  
 
Acute rejection after renal transplantation is uncommon after one year.  When it does occur, 
it is associated with a poor prognosis for graft survival and may be caused by poor patient 
compliance. This will be the same for the new, as well as the conventional, 
immunosuppressive strategies. 
 
The treatment of steroid resistant or refractory rejection has been assumed in this paper to 
be with polyclonal or monoclonal antibodies. However, it is clear that the majority of UK 
renal transplant units are increasingly using tacrolimus in place of antibody therapies in this 
situation since it is effective, more patient friendly, and can be given by mouth as an out-
patient.
3,4
  
 
The high withdrawal rate, due to side-effects in both the tacrolimus and mycophenolate 
mofetil studies, has previously been alluded to and it is clear that side-effects are principally 
dose dependent. Patients and their medical attendants are always extra vigilant in clinical 
trials and patients are withdrawn and the drug discontinued at an earlier stage than might 
normally happen in routine clinical practice if side-effects are observed. Once experience 
has been gained in the use of a new drug, the clinician has more confidence in continuing to 
use it or to reduce the dose depending on response and side-effects. As a result of the 
tacrolimus studies, lower maintenance doses are now recommended once a therapeutic 
response has been obtained. The withdrawal rates for side-effects in the mycophenolate 
mofetil studies were greater in the 3mg than the 2mg group and, as a result, 1mg twice daily 
is now recommended. 
 
It should be noted that this report focuses on renal transplantation in adults.  Children justify 
special consideration because one of the major benefits of transplantation in children is to 
enable them to grow satisfactorily, incidentally saving on potentially expensive treatments, 
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such as, growth hormone therapy, and for them to achieve their school and developmental 
potential.  It is essential that the best graft function possible is achieved and the use of 
these newer agents would enable a reduction of acute rejection.  This may, in turn, reduce 
the incidence of chronic rejection and the need for the child to undergo further transplants 
either in late childhood or early adulthood.  A lot of focus in the document is on saving 
kidneys in the long-term from rejection and this is of major importance in children. 
 
Body image considerations are also of major importance in children and may be a factor in 
non-compliance with treatment which particularly affects the adolescent group. Therefore, 
drugs which do not result in excess hair growth or enlarged gums or major changes in body 
image are to be encouraged. These are further reasons to consider tacrolimus or 
mycophenolate mofetil with reduced steroid dosage in the future. 
 
The analysis of drug costs presented in this report is based on typical drug doses for an 
adult population and, since doses are based upon body size, does not apply directly to 
children where doses are likely to be markedly less.  Furthermore, since children may be 
travelling from further afield to a single regional centre, the cost of travel is likely to be very 
relevant as increased out-patient and in-patient attendance will lead to increased cost.  An 
economic analysis for the use of these new drugs in a paediatric population is, therefore, 
likely to be improved in comparison to their adult population analysis. 
 
It is clear that tacrolimus and mycophenolate mofetil are potent immunosuppressive agents 
and, as such, may increase the risk of infectious complications and malignancy. One 
important principle of transplantation is to establish the balance between under and over 
immunosuppression; on the one hand to minimise the risk of rejection whilst on the other 
minimising the risks of infectious complications and malignancy. Since approximately 50% 
of patients will not experience acute rejection, it can be argued that this group can be 
maintained on conventional cyclosporin based therapy, accepting the morbidity associated 
with the potential long-term usage of steroids. It is the groups which experience severe, 
recurrent or late rejection which would particularly benefit from tacrolimus or mycophenolate 
mofetil based immunosuppression. Although this group cannot be predicted accurately, 
there are certain factors which render an individual immunologically at high risk; these 
include: 
 loss of previous transplant to acute rejection; 
 the presence of more than 50% cytotoxic antibodies; 
 third or subsequent transplant.  
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